Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial

Fig. 1

MRI lesions at Week 96: a new T1 hypointense lesions; b new-active lesions Gd+, gadolinium-enhancing lesions. MRI analysis population (ITT population dosed in Year 2 with at least 1 MRI result). a P values based on multiple logit regression, adjusted for baseline number of T1 lesions. b P values based on negative binomial regression, adjusted for baseline number of Gd + lesions

Back to article page